ATR vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AptarGroup exhibits strong financial health with a Piotroski F-Score of 8/9, indicating robust fundamentals and consistent profitability. The company trades below its growth-based intrinsic value of $186.14 but at a premium to its Graham defensive value of $77.42, reflecting reasonable valuation given its earnings momentum. Despite solid ROE of 15.62% and low debt/equity of 0.46, insider selling and weak technical trend signal caution. Analysts recommend a 'buy' with a target price of $159.14, implying 26% upside, though recent price performance remains negative over the past year.
JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ATR vs JNJ: Head-to-Head Comparison
This page compares AptarGroup, Inc. (ATR) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.